Skip to main content
. 2024 Feb 5;2024(2):CD015219. doi: 10.1002/14651858.CD015219.pub2

Bosaeed 2022.

Study characteristics
Methods Double‐blinded RCT
Participants Outpatients with confirmed COVID‐19 (mild‐ambulatory) treated in 7 centres in Saudi Arabia
Interventions Favipiravir, placebo
Outcomes Time from start of treatment to viral clearance, defined as the conversion of SARS‐CoV‐2 RT‐PCR from positive to negative within 15 days; symptom resolution; hospitalization; intensive care unit admissions; adverse events; and 28‐day mortality
Notes